ReviewDiagnostics (Basel, Switzerland)2020
Early Diagnosis of Pancreatic Cancer: The Key for Survival.
Review in Diagnostics (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Salivary metabolites for pancreatic cancer diagnosis: a systematic review and meta-analysis.BMC gastroenterology · 2025Pooled it
- Cancer in transition: discovery of tumor-intrinsic transcriptional programs shaping the immune and microenvironmental landscape.Biomarker research · 2026Review
- Comorbidities, medication use, and overall survival in eight cancers: a multinational cohort study of 1.7 million patients across Europe.The Lancet regional health. Europe · 2026Article
- Impact of good glycemic control on survival of pancreatic ductal adenocarcinoma with diabetes mellitus.BMC gastroenterology · 2026Article
- Mesenchymal Stem Cell Exosome-Mediated Delivery of Paclitaxel for Pancreatic Cancer Therapy.Biomolecules · 2026Article
- Role of Probiotics in Enhancing Immune Function and Improving the Effectiveness of Treatments for Pancreatic Cancer.Microorganisms · 2025Review
- Circulating miRNAs as Non-Invasive Biomarkers in Pancreatic Cancer: A Two-Phase Plasma-Based Study.Journal of clinical medicine · 2025Article
- Small pancreatic ductal adenocarcinoma (≤ 2 cm): different imaging and clinicopathologic features according to extrapancreatic extension.Abdominal radiology (New York) · 2025Article
- Advances in pancreatic cancer epigenetics: From the mechanism to the clinic.World journal of gastrointestinal oncology · 2025Review
- Advancing Antibody-Drug Conjugates: Precision Oncology Approaches for Breast and Pancreatic Cancers.Cancers · 2025Review
- Exploring the Link Between Nutritional and Functional Status and Short-Term Postoperative Outcomes in Patients Undergoing Pancreatic Cancer Surgery.Life (Basel, Switzerland) · 2025Article
- Assessing Implantation Sites for Pancreatic Islet Cell Transplantation: Implications for Type 1 Diabetes Mellitus Treatment.Bioengineering (Basel, Switzerland) · 2025Review
- Personalized medicine in pancreatic cancer: Harnessing the potential of mRNA vaccines.Journal, genetic engineering & biotechnology · 2025Article
- c-Myc inhibition and p21 modulation contribute to unsymmetrical bisacridines-induced apoptosis and senescence in pancreatic cancer cells.Pharmacological reports : PR · 2025Article
- Extracellular derived-exosomal micrornas in pancreatic cancer: investigating their diagnostic importance and potential targets for the prevention and treatment in pancreatic cancer.Frontiers in oncology · 2025Review
- Oral microbiome as a diagnostic biomarker for pancreatic cancer: a systematic review and meta-analysis of diagnostic accuracy.Journal of oral microbiology · 2025Review
- Mesenchymal stem cell-delivered paclitaxel nanoparticles exhibit enhanced efficacy against a syngeneic orthotopic mouse model of pancreatic cancer.International journal of pharmaceutics · 2024Article
- Advancing frontline early pancreatic cancer detection using within-class feature extraction in FTIR spectroscopy.Scientific reports · 2024Article
- Canadian National Pancreas Conference 2023: A Review of Multidisciplinary Engagement in Pancreatic Cancer Care.Current oncology (Toronto, Ont.) · 2024Article
- Progression in Near-Infrared Fluorescence Imaging Technology for Lung Cancer Management.Biosensors · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic cancer (PC) is one of the most aggressive forms of cancer. Negative prognosis is mainly due to the late diagnosis in advanced stages, when the disease is already therapeutically overcome. Studies in recent years have focused on identifying biomarkers that could play a role in early diagnosis, leading to the improvement of morbidity and mortality. Currently, the only biomarker widely used in the diagnosis of PC is carbohydrate antigen 19-9 (CA19.9), which has, however, more of a prognostic role in the follow-up of postoperative recurrence than a diagnostic role. Other biomarkers, recently identified as the methylation status of ADAMTS1 (A disintegrin and metalloproteinase with thrombospondin motifs 1) and BNC1 (zinc finger protein basonuclin-1) in cell-free deoxyribonucleic acid (DNA), may play a role in the early detection of PC. This review focuses on the diagnosis of PC in its early stages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.